NasdaqCM - Nasdaq Real Time Price USD

enGene Holdings Inc. (ENGN)

6.70

-0.40

(-5.64%)

As of 12:41:07 PM EST. Market Open.

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

BOSTON & MONTREAL, January 30, 2025--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today announced three poster presentations at the 2025

Business Wire yesterday

ENGN
-5.64%
ENGNW
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL, December 30, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), today reported the grant of inducement equity awards to

Business Wire last month

ENGN
-5.64%
ENGNW
enGene Reports Full Year 2024 Financial Results and Provides a Business Update

BOSTON & MONTREAL, December 19, 2024--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), announced its financial results for the full year en

Business Wire last month

ENGN
-5.64%
ENGNW
enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL, November 25, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Alex Nichols, Ph.D., Chief Strateg

Business Wire 2 months ago

ENGN
-5.64%
ENGNW
With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners

Key Insights Significantly high institutional ownership implies enGene Holdings' stock price is sensitive to their...

Simply Wall St. 2 months ago

ENGN
-5.64%
ENGNW
enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

BOSTON & MONTREAL, November 05, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that Ron Cooper, Chief Executive Office

Business Wire 2 months ago

ENGN
-5.64%
ENGNW
enGene Announces $60 Million Private Placement Financing

BOSTON & MONTREAL, October 25, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that it has agreed to sell 6,758,311 of

Business Wire 3 months ago

ENGN
-5.64%
ENGNW
enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL, October 22, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today reported the grant of an inducement equity award t

Business Wire 3 months ago

ENGN
-5.64%
ENGNW
enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

BOSTON & MONTREAL, October 21, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced the appointment of Joan Connolly as Chie

Business Wire 3 months ago

ENGN
-5.64%
ENGNW
Insider Buys Additional US$57k In enGene Holdings Stock

Whilst it may not be a huge deal, we thought it was good to see that the enGene Holdings Inc. ( NASDAQ:ENGN ) Chief...

Simply Wall St. 3 months ago

ENGN
-5.64%
ENGNW
Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

BOSTON & MONTREAL, September 26, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), is a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid (also known as detalimogene, and previously EG-70) is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis). Today, the Company announced preliminary data from

Business Wire 4 months ago

ENGN
-5.64%
ENGNW
enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

BOSTON & MONTREAL, September 10, 2024--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), announced its financial results for the third quart

Business Wire 4 months ago

ENGN
-5.64%
ENGNW
enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

BOSTON & MONTREAL, July 24, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced the grant of an inducement equity award to Ron Cooper, the Company’s newly-appointed Chief Executive Officer.

Business Wire 6 months ago

ENGN
-5.64%
ENGNW
enGene Announces Appointment of Ron Cooper as Chief Executive Officer

BOSTON & MONTREAL, July 24, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk Non-Muscle Invasive Bladder Cancer (NMIBC), today announced that Ron Cooper has joined the Company as Chief Executive Officer and member of the Board of Directors, effective July 22, 2024. This transition follows a previously announced successio

Business Wire 6 months ago

ENGN
-5.64%
ENGNW
NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

NAARDEN, The Netherlands and MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointments of Mark C. McKenna and Wouter Jo

GlobeNewswire 6 months ago

APGE

NAMS
+5.48%
NAMSW
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

BOSTON & MONTREAL, June 14, 2024--enGene Holdings Inc. (Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high-risk non-muscle invasive bladder cancer (NMIBC), today announced its financial results for the second quarter ended April 30, 2024, and provided a business update.

Business Wire 7 months ago

ENGN
-5.64%
ENGNW
enGene to Present at the Jefferies Global Healthcare Conference

BOSTON & MONTREAL, May 29, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Jason Hanson, Chief Executive Officer, will present a corporate overview at the Jefferies Global Healthcare Conference in New York City, on June 5, 2024, at 12:30 p.m. ET.

Business Wire 7 months ago

ENGN
-5.64%
ENGNW
enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

BOSTON & MONTREAL, May 15, 2024--enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the election of Paul Hastings and Wouter Joustra as new members of its Board of Directors at the Company’s 2024 annual meeting of shareholders. Shareholders also reelected incumbent director Lota Zoth. Each will serve a

Business Wire 8 months ago

ENGN
-5.64%
ENGNW
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

enGene Holdings Inc. (Nasdaq: ENGN) or ("enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced an oral presentation at the American Urology Association (AUA) 2024 Annual Meeting being held May 3-6, 2024 in San Antonio, Texas.

CNW Group 8 months ago

ENGN
-5.64%
ENGNW
/C O R R E C T I O N -- enGene Inc./

enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that Raj Pruthi MD MHA FACS has joined the Company as SVP, Urologic Oncology and Clinical Development, reporting to enGene's Chief Medical Officer, Dr. Richard Bryce. In this role, Dr. Pruthi's responsibilities will include sup

CNW Group 9 months ago

ENGN
-5.64%
ENGNW

Performance Overview

Return	ENGN	S&P 500
YTD	-0.75%	+3.49%
1-Year	-10.67%	+24.12%
3-Year	-32.26%	+37.93%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

enGene Holdings Inc. (ENGN)

enGene to Present Three Posters at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) Highlighting the Ongoing Clinical Development of Detalimogene Voraplasmid for the Treatment of Non-Muscle Invasive Bladder Cancer (NMIBC)

enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

enGene Reports Full Year 2024 Financial Results and Provides a Business Update

enGene to Participate in Upcoming Investor Conferences

With 52% ownership of the shares, enGene Holdings Inc. (NASDAQ:ENGN) is heavily dominated by institutional owners

enGene to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

enGene Announces $60 Million Private Placement Financing

enGene Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Appoints Joan Connolly as Chief Technology Officer and Anthony Cheung, Ph.D., as Chief Scientific Officer

Insider Buys Additional US$57k In enGene Holdings Stock

Detalimogene Demonstrates 71% Complete Response Rate at Any Time in Preliminary Analysis of LEGEND Pivotal Cohort

enGene Reports Third Quarter 2024 Financial Results and Provides a Business Update

enGene Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

enGene Announces Appointment of Ron Cooper as Chief Executive Officer

NewAmsterdam Pharma Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors

enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update

enGene to Present at the Jefferies Global Healthcare Conference

enGene Announces the Election of Paul Hastings and Wouter Joustra to its Board of Directors

enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting

/C O R R E C T I O N -- enGene Inc./

Performance Overview